C4 Therapeutics Inc
CCCC2.440USD
+0.060+2.52%
Close 11/21, 16:00（ET）Quotes delayed by 15 min
180.99MMarket Cap
LossP/E TTM
More Details of C4 Therapeutics Inc Company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.
C4 Therapeutics Inc Info
Ticker SymbolCCCC
Company nameC4 Therapeutics Inc
IPO dateOct 02, 2020
CEOMr. Andrew J. Hirsch
Number of employees110
Security typeOrdinary Share
Fiscal year-endOct 02
Address490 Arsenal Way
CityWATERTOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02472
Phone16172310700
Websitehttps://c4therapeutics.com/
Ticker SymbolCCCC
IPO dateOct 02, 2020
CEOMr. Andrew J. Hirsch
Company Executives of C4 Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
168.59K
+2.10%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
118.56K
+12.91%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
Ms. Jolie M. Siegel, J.D.
Ms. Jolie M. Siegel, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Courtney Solberg
Ms. Courtney Solberg
Senior Manager - Investor Relations
Senior Manager - Investor Relations
--
--
Dr. Laura Bessen, M.D.
Dr. Laura Bessen, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
168.59K
+2.10%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
118.56K
+12.91%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Point72 Asset Management, L.P.
8.75%
RA Capital Management, LP
8.25%
Lynx1 Capital Advisors LLC
7.32%
Soleus Capital Management, L.P.
7.28%
OrbiMed Advisors, LLC
5.40%
Other
62.99%
Shareholders
Shareholders
Proportion
Point72 Asset Management, L.P.
8.75%
RA Capital Management, LP
8.25%
Lynx1 Capital Advisors LLC
7.32%
Soleus Capital Management, L.P.
7.28%
OrbiMed Advisors, LLC
5.40%
Other
62.99%
Shareholder Types
Shareholders
Proportion
Hedge Fund
24.96%
Investment Advisor
17.67%
Venture Capital
8.41%
Investment Advisor/Hedge Fund
8.17%
Research Firm
7.96%
Private Equity
5.40%
Corporation
5.03%
Individual Investor
2.44%
Pension Fund
0.09%
Other
19.87%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
300
54.93M
57.11%
-28.27M
2025Q2
314
71.31M
100.42%
-15.50M
2025Q1
338
73.30M
106.72%
-7.68M
2024Q4
337
73.17M
103.10%
-6.50M
2024Q3
332
72.91M
103.31%
-3.42M
2024Q2
325
69.49M
100.73%
-3.96M
2024Q1
329
66.54M
97.72%
+3.15M
2023Q4
324
51.20M
103.91%
-2.36M
2023Q3
320
38.85M
79.00%
-14.16M
2023Q2
326
38.30M
78.08%
-12.52M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lynx1 Capital Advisors LLC
7.10M
9.97%
--
--
Jun 30, 2025
Soleus Capital Management, L.P.
6.98M
9.81%
--
--
Jun 30, 2025
OrbiMed Advisors, LLC
6.83M
9.6%
--
--
Jun 30, 2025
Betta investment Hong Kong Ltd
4.87M
6.85%
-693.38K
-12.45%
Apr 22, 2025
Morgan Stanley & Co. LLC
3.15M
4.43%
+703.45K
+28.70%
Jun 30, 2025
Wasatch Global Investors Inc
7.42M
10.43%
-48.67K
-0.65%
Jun 30, 2025
The Vanguard Group, Inc.
3.02M
4.24%
-352.86K
-10.47%
Jun 30, 2025
BofA Global Research (US)
2.01M
2.82%
+17.18K
+0.86%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Fidelity Enhanced Small Cap ETF
0.01%
iShares Biotechnology ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
View more
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
iShares Micro-Cap ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
Fidelity Enhanced Small Cap ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of C4 Therapeutics Inc?
The top five shareholders of C4 Therapeutics Inc are:
Lynx1 Capital Advisors LLC holds 7.10M shares, accounting for 9.97% of the total shares.
Soleus Capital Management, L.P. holds 6.98M shares, accounting for 9.81% of the total shares.
OrbiMed Advisors, LLC holds 6.83M shares, accounting for 9.60% of the total shares.
Betta investment Hong Kong Ltd holds 4.87M shares, accounting for 6.85% of the total shares.
Morgan Stanley & Co. LLC holds 3.15M shares, accounting for 4.43% of the total shares.
Lynx1 Capital Advisors LLC holds 7.10M shares, accounting for 9.97% of the total shares.
Soleus Capital Management, L.P. holds 6.98M shares, accounting for 9.81% of the total shares.
OrbiMed Advisors, LLC holds 6.83M shares, accounting for 9.60% of the total shares.
Betta investment Hong Kong Ltd holds 4.87M shares, accounting for 6.85% of the total shares.
Morgan Stanley & Co. LLC holds 3.15M shares, accounting for 4.43% of the total shares.
What are the top three shareholder types of C4 Therapeutics Inc?
The top three shareholder types of C4 Therapeutics Inc are:
Point72 Asset Management, L.P.
RA Capital Management, LP
Lynx1 Capital Advisors LLC
Point72 Asset Management, L.P.
RA Capital Management, LP
Lynx1 Capital Advisors LLC
How many institutions hold shares of C4 Therapeutics Inc (CCCC)?
As of 2025Q3, 300 institutions hold shares of C4 Therapeutics Inc, with a combined market value of approximately 54.93M, accounting for 57.11% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -43.32%.
What is the biggest source of revenue for C4 Therapeutics Inc?
In --, the -- business generated the highest revenue for C4 Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
